

2nd International CIK Cell Conference From bench to bedside...and back

Fondazione M. Tettamanti, IRCCS San Gerardo dei Tintori, Monza (Italy)

Scientific Program Chairs: Marta Serafini and Sarah Tettamanti

Scientific Committee:

Marta Serafini, Sarah Tettamanti, Antonio Rosato, Roberta Sommaggio, Elisa Capuzzello

WELCOME

09:30 Prof. ANDREA BIONDI and Prof. INGO SCHMIDT-WOLF

09:45-10:30 LECTURE PROF. DARIO SANGIOLO

“CAR CIK as innovative strategy against chemoresistant solid tumors”

BASIC and PRECLINICAL RESEARCH on CIK cells

10:30-10:50 ANTONIO ROSATO “CD19/CD20 mAb-engaged Cytokine Induced Killer (CIK) Cells can represent an effective alternative of CD19 CAR-T in adoptive immunotherapy of B-cell malignancies”

10:50-11:10 AMIT SHARMA “Expanding the role of CIK cell therapy and its evolving applications”

11:10-11:30 JINGJING PU “Tandem CAR-CIK and Beyond: Optimizing Cell Therapy for Multiple Myeloma”

11:30 COFFEE BREAK

12:00-12:20 MARTINO INTRONA “Transposon mediated anti human tenascin C targeting solid tumors”

12:20-12:50 MARTA SERAFINI “Directing CAR-CIK cells homing to the acute myeloid leukemia bone marrow niche”

LUNCH 12:50-13:45

13:45-14:30 LECTURE PROF. ALESSANDRO RAMBALDI

“Donor-derived cytokine induced killer (CIK) cells for the treatment of leukemia relapse after allo-HSCT”

NEXT to the CLINIC: HEMATOLOGIC MALIGNANCIES and SOLID CANCERS

14:30-14:50 KEVIN A. FENIX “CIK cell therapy for metastatic colorectal cancer treatment in South Australia”

14:50-15:10 XIUBAO REN “A randomized, multicenter, open-label phase II study to evaluate autologous CIK cell immunotherapy in combination with PD-1 inhibitor and chemotherapy as the first-line treatment of stage IV NSCLC (CCICC-002b)”

15:10-15:30 SARAH TETTAMANTI “Non-viral Sleeping Beauty-engineered Dual CAR-CIK cells for the treatment of Acute Myeloid Leukemia”

BEST ABSTRACTS

15:30- 16:10 3 presentations (10 min+ 2 min questions)

16:15- 16:30: MARTA DOSSENA “ How to simplify cytokine integration into a ATMPs manufacturing process”

ROUND TABLE

16:30-17:00

CONCLUDING REMARKS